Parkinsonism, chorea, and dystonia are well-known clinical manifestations of Creutzfeldt-Jakob disease (CJD), but lesions of the nigrostriatal pathway have never been thoroughly studied. We performed a detailed neuropathologic study of the nigrostriatal pathway in 15 sporadic CJD and 2 variant CJD cases that included clinical correlations and assessment of neuron subtype loss, distribution of prion protein, >-synuclein, ubiquitin, and 14-3-3 aggregation. We found evidence of nigrostriatal pathway damage in these CJD cases. Dopaminergic neurons and striatal outflow neurons were markedly affected in sporadic CJD, whereas cholinergic interneurons were spared. In cases of CJD with chorea or myoclonus, there was less presynaptic dopaminergic loss than in cases of CJD with parkinsonism. The 2 variant CJD cases with parkinsonism or chorea showed severe cholinergic interneuron loss in the caudate and putamen, a pattern that differed from that found in sporadic CJD. >-Synuclein, ubiquitin, and 14-3-3 aggregation coexisted with prion protein aggregation, thereby generating mixed pathological features. These findings suggest a possible pathophysiological overlap of abnormal protein aggregation in CJD and Parkinson disease.
INTRODUCTION
Although parkinsonism, chorea, and dystonia are wellknown clinical manifestations of sporadic (sCJD) and variant Creutzfeldt-Jakob disease (vCJD) (1Y3), little is known about the neuropathology of the nigrostriatal pathway in these disorders. In particular, the loss of nigral dopaminergic cells and striatal cell populations and their clinical correlates have not been investigated in detail. Lewy bodies, the cytopathological hallmark of Parkinson disease (PD) (4), have occasionally been reported in CJD (5Y7), suggesting the possibility of a pathophysiological overlap of abnormal protein aggregation in these diseases. This hypothesis prompted a thorough neuropathologic study of the nigrostriatal pathway in a series of 17 consecutive CJD cases; the study included assessments of neuron subtype loss and the distribution of prion protein (PrP), >-synuclein, ubiquitin, and 14-3-3 aggregation.
MATERIALS AND METHODS

Study Population
We studied 17 CJD cases with well-documented clinical histories collected from 2000 to 2007. There were 15 sCJD and 2 vCJD cases. Autopsy and pathological processing of the brains were performed according to the neuropathologic procedure of the French Reference Center for Spongiform Encephalopathies. The ages at death of the 8 men and 9 women ranged from 23 to 84 years (mean, 67.6 T 3.6 years); the mean disease duration was 12.9 T 2.4 months. Information regarding the genetic and molecular subtype of scrapie PrP (PrP Sc ) was obtained from the French Reference Center for Spongiform Encephalopathies. Clinical data were retrospectively collected from medical files obtained from the neurological unit where the patients had been followed until their death. Parkinsonism was defined as the association of akinesia/bradykinesia with extrapyramidal rigidity. Brains from 2 men and 3 women with ages ranging from 39 to 85 years (mean, 70.2 T 8 years) without any evidence of neurological disorders and with normal neuropathologic findings at autopsy served as controls. The causes of death of the control patients were cardiovascular disease or cancer.
Neuropathologic Evaluation
Formalin-fixed paraffin-embedded materials from the substantia nigra and the striatum were available for all patients. The substantia nigra was studied within a horizontal 5-mm-thick section through the brainstem at the junction of midbrain and diencephalons; the striatum was studied within a coronal 5-mm-thick section demonstrating connections between the head of the caudate and the putamen across the internal capsule. Neuronal loss, astrogliosis, and Lewy body formation were preliminary appreciated on routine hematoxylin and eosinYstained paraffin sections.
Prion protein immunostaining was performed on sections from the substantia nigra, caudate, and putamen with antibody 12F10 (SPI-BIO, Montreal, Canada) after protease K digestion. The same areas were immunostained for >-synuclein (mouse monoclonal antibody, clone LB509, Zymed, Montrouge, France) and ubiquitin (rabbit polyclonal antibody, Dako, Trappes, France) to identify Lewy bodies and for 14-3-3 A protein (mouse monoclonal antibody H-8, Santa Cruz Biotechnology, Santa Cruz, CA).
Dopaminergic neurons in the substantia nigra were counted in sections immunostained with a mouse antityrosine hydroxylase monoclonal antibody (Abcys, Paris, France); cholinergic interneurons in caudate and putamen were counted in sections immunostained with a goat anti-substance P receptor (anti-NK1 receptor) polyclonal antibody (Santa Cruz Biotechnology). Cresyl violet staining was used to assess the density of medium-sized spiny neurons, that is, GABAergic neurons that represent most of the efferent pathways from the striatum. Medium-sized spiny neurons were identified as medium-sized cells with nonindented nuclei, moderate amounts of cytoplasm, and radiating neurites; reactive astrocytes had a large, clear, and fibrillar cytoplasm (Figs. 1A, B) . Neuron subtypes were counted when the cell nucleus was in the section plane; neurons were counted in 10 randomly selected optical fields under a 20Â objective, as previously described on CJD autopsy material (8, 9) .
Statistical Analysis
All data are expressed as mean T SEM. Age at death, disease duration, and cell count data were normally distributed (Kolmogorov-Smirnov test, p 9 0.05). Correlations were performed using linear regressions. Comparisons between subgroups of CJD patients were performed using a 2-tailed unpaired t-test or unpaired t-test with Welch corrections when variances were found to be different (F test). Comparisons of cell counts between controls and CJD patients were performed using a 2-tailed unpaired t-test. Statistical analyses were performed using GraphPad Prism V4.0. For all statistical tests, p G 0.05 was considered significant.
RESULTS
Clinical Features
Major clinical and molecular characteristics of the 17 CJD cases are given in Table 1 .
Myoclonus was present in 16 patients; characteristic periodic sharp-wave complexes in the electroencephalogram were present in 12 cases. Twelve patients had both parkinsonism and myoclonus. Parkinsonism was observed in the terminal stages of CJD in 11 of 12 cases in the form of akinetic mutism in 7 patients but was a presenting feature in Case 1. Ages at death and disease durations of the 12 CJD patients with parkinsonism were not different from the 5 patients without parkinsonism (ages at death, 70.1 T 2.3 vs 61.8 T 11.4 years, p = 0.52; disease duration, 12.8 T 3.2 vs 13.2 T 3.5 months, p = 0.94). Two patients had chorea (2/2); this was associated with myoclonus in 1 of these patients; 3 patients had only myoclonus. None of the cases had dystonia.
There was no correlation between the occurrence of movement disorders and the age at death, duration of the disease, and status on codon 129 or PrP Sc type. One of the 2 patients who had chorea was a 23-year-old vCJD patient who also had painful sensory symptoms in the lower limbs; magnetic resonance imaging showed a high signal in both pulvinars.
Neuropathology in the Nigrostriatal Pathway
Neuropathologic findings are summarized in Table 2 .
PrP Accumulation
Prion protein deposits were found in the substantia nigra in 64.7% of CJD patients (11/17) , in the caudate in 94.1% (16/17) , and in the putamen in all cases. In patients with parkinsonism, PrP deposits were found in the substantia nigra in 66.6% (8/12) (Fig. 1C) , in the caudate in 91.6% (11/12) , and in the putamen in 100% (12/12). Both patients with chorea had PrP accumulations in the substantia nigra (Fig. 1F) , caudate, and putamen. In the 3 remaining CJD patients who had neither parkinsonism nor chorea but did 
Lewy Bodies and Lewy Neurites
>-SynucleinYpositive and ubiquitinated Lewy bodies and/or Lewy neurites were present in the substantia nigra or the striatum in 23.5% CJD patients (4/17) and in 25% (3/12) cases with parkinsonism (Fig. 1D) . The durations of illness for these 3 CJD cases were 11, 24, and 42 months, respectively, which was not different from the 14 other cases (25.7 T 8.9 vs 10.1 T 2.2 months, p = 0.23); ages at death were also not significantly different (72.7 T 3.1 vs 69.2 T 2.9 years, p = 0.55). In one of these 3 cases, there was no co-occurrence of >-synucleinYpositive Lewy body and PrP deposits in the substantia nigra, although >-synucleinYpositive Lewy neurites and PrP coexisted in the striatum in all 3 cases. >-SynucleinYpositive and ubiquitinated Lewy bodies and Lewy neurites were also found in the substantia nigra of the vCJD case who had chorea and myoclonus (Figs. 1G, H) ; the duration of illness for this patient was 12 months, and the age at death was 23 years. There was no colocalization of PrP and >-synuclein evident in consecutive immunostained sections.
The pale 14-3-3 immunopositivity that was observed in some neuronal somata and processes in the controls (Fig. 1I ) was preserved and even stronger in some surviving neurons of the CJD cases (Fig. 1J ). This 14-3-3 immunostaining was even stronger in Lewy bodies and Lewy neurites (Fig. 1K) in the 4 CJD cases with these features.
Differential Loss of Neuronal Subpopulations
There was a significant loss of dopaminergic neurons in the substantia nigra in all 17 CJD cases compared with controls (average loss, 69.5%; range, 38.8%Y92.3%; mean number of neurons, 71.7 T 9.9 vs 235.4 T 24.8, p G 0.0001) (Fig. 1E) . Cell counts of dopaminergic neurons did not correlate with age at death or disease duration. Among the CJD patients, those who had parkinsonism had greater neuronal loss in the substantia nigra compared with patients who displayed myoclonus only (78.7% vs 44.1%; mean number of neurons, 50.2 T 6.8 vs 131.7 T 7.2, p G 0.0001) or compared with patients who had chorea (78.7% vs 53.1%; mean number of neurons, 50.2 T 6.8 vs 110.5 T 20.5, p G 0.01).
The CJD patients displayed cell loss in the putamen (Figs. 1A, B) . The numbers of medium-sized spiny neurons were significantly decreased compared with controls with an average loss of 42.5% (range, 10.1%Y83.9%; mean number of neurons, 286.4 T 19.9 vs 498.2 T 23.9, p G 0.0001). There was also a trend toward a greater loss of medium-sized spiny neurons in the putamen of patients with parkinsonism The caudate nucleus was also affected in all CJD patients. The medium-sized spiny neuron numbers were significantly decreased with an average loss of 46.9% (range, 28.8%Y87.7%) compared with controls (mean number of neurons, 291.1 T 20.1 vs 548.2 T 20.7, p G 0.0001). Cell counts in the substantia nigra and the striatum were linearly correlated (caudate, r = 0.76, p G 0.0001; putamen, r = 0.72, p G 0.001) (Fig. 2) .
In the caudate and putamen, there was no significant loss of cholinergic interneurons in sCJD patients compared with controls (caudate, 24.5 T 1.9 vs 21.8 T 1.3; putamen, 28.9 T 1.8 vs 27.8 T 2.4). There was a marked loss of cholinergic interneurons in the caudate (4 T 1, p G 0.001) and putamen (3.5 T 0.5, p G 0.01) in the 2 vCJD patients, that is, one who had parkinsonism and myoclonus and the other who had had chorea and myoclonus.
DISCUSSION
This study provides the first detailed analysis of the nigrostriatal pathway in patients with CJD. All 17 patients studied had a combination of presynaptic and postsynaptic cell loss in the nigrostriatal system characterized by a marked loss of dopaminergic neurons in the substantia nigra and a loss of GABAergic medium-sized spiny outflow striatal neurons. Dopaminergic loss in the substantia nigra correlated with neuronal loss in the caudate and putamen, supporting the notion of a parallel presynaptic and postsynaptic degeneration of the nigrostriatal pathway in CJD. These alterations were particularly prominent in the 12 patients who had parkinsonism. In those cases, there was severe loss (78.7%) of dopaminergic neurons in the substantia nigra, indicating a profound degeneration of the dopaminergic nigrostriatal pathway. This finding is in agreement with a recent observation obtained in vivo by single-photon emission computed tomography of the dopamine transporter showing a dopaminergic deficit in an sCJD case with extrapyramidal rigidity (10) . Medium-sized spiny neurons were also markedly damaged in the caudate and putamen in CJD cases with parkinsonism, a combination of presynaptic and postsynaptic degeneration reminiscent of that found in the striatonigral degeneration type of multiple system atrophy (11) . Disturbances of inhibitory GABAergic mechanisms have been suggested to explain the commonly observed myoclonus in CJD (8) . Similarly, a predominant loss of inhibitory neurons in the reticular thalamus has been reported in sCJD cases with typical electroencephalogram changes and myoclonus (9) . Interestingly, large cholinergic interneurons (those bearing NK1 receptors) were spared. This is reminiscent of the pattern of neuronal loss observed in the caudate-putamen of both striatonigral degeneration type of multiple system atrophy (12) and Huntington disease (13) . The differential vulnerability of medium-sized spiny neurons and cholinergic interneurons may rely upon their cytochemical and intrinsic electrophysiological characteristics (14) .
There was also a loss of dopaminergic neurons in the substantia nigra in the 2 patients who had chorea, but this was less marked than the loss in those with parkinsonism; both CJD patients with chorea had a marked loss of striatal medium-sized spiny neurons.
The finding of a severe loss of cholinergic interneurons in the caudate and putamen from the 2 vCJD cases either with parkinsonism or chorea is of particular interest. This result highlights a difference in the pathology between sCJD and vCJD at the level of the nigrostriatal system. Such peculiar vulnerability of cholinergic interneurons may underlie some of the differences in the clinical manifestations between these forms of CJD. So far, pulvinar lesions found in vCJD have been incriminated in the occurrence of chorea, sensory deficit, and/or painful sensory symptoms (3, 15) . The degeneration of striatal cholinergic interneurons may also participate in the clinical expression of vCJD.
Lewy bodies and/or Lewy neurites were found in the substantia nigra and the striatum of 4 cases; they were also immunopositive for >-synuclein, ubiquitin, and 14-3-3. This finding was observed in patients with parkinsonism but also in the vCJD patient with chorea. The occurrence of PD pathology has been reported in a few CJD cases (5Y7), including Case 7 in the present series. Among the factors that might have contributed to this cytopathological overlap in CJD with parkinsonism, the patient ages (i.e. 69, 70, and 79 years) may play a role. The complete neuropathologic study procedure of the French Reference Center for Spongiform Encephalopathies includes assessment of neuronal loss and Lewy bodies in the locus caeruleus (data not shown). These patients may have had coexistent incidental Lewy body disease, which is known to occur with a frequency of 4.9% (16) or 4.7% (17) in 2 previous studies and in up to 10% of normal subjects older than 60 years (18, 19) . The prevalence of Lewy bodies in our series (23.5%), however, is higher than the 10% expected in normal subjects in that age range; their presence in the substantia nigra of the 23-year-old vCJD patient with chorea argues against the incidental Lewy body disease hypothesis. Indeed, based upon clinical and neuropathologic data, overlapping pathogenetic mechanisms in neurodegenerative disorders are becoming more recognized (20) . For example, oxidative stress contributes to neurodegeneration in PD (21) as well as in CJD (22) . Because PrP accumulation was granular and extraneuronal in all of our CJD cases and there was coexistence of perineuronal positivity in only 2 cases, we could not demonstrate colocalization of PrP with >-synuclein aggregation in Lewy bodies and Lewy neurites. We do not believe, however, that this necessarily contradicts the concept of a pathophysiological overlap of abnormal protein aggregation in CJD and PD. >-SynucleinYimmunoreactive granular deposits have also been observed in the brains of scrapie-affected animals (23, 24) , and they were prominent in the cerebellar cortex of CJD cases with disease durations of more than 1 year (23). This suggests that perturbation of >-synuclein metabolism can occur in prion diseases. Lewy bodies develop during the several years' duration of PD, and an intriguing possibility is that >-synuclein pathology found in the nigrostriatal pathway of CJD cases might become more evident if the course of CJD was longer. Because 14-3-3 proteins are elevated in the cerebrospinal fluid from most patients with CJD and immunohistochemical localization of 14-3-3 has been reported in Lewy bodies (25) , the increased degrees of 14-3-3 immunostaining associated with Lewy bodies in 4 CJD cases further support the suggestion of pathophysiological overlap in abnormal protein aggregation in CJD and PD.
Lewy body formation might reflect one of several response patterns by the human brain to injury (26) . Under normal physiological conditions, equilibrium is essentially shifted toward the native unfolded conformation of >-synuclein. Different triggers (e.g. PD-related mutations and numerous other environmental factors) are able to shift this equilibrium, thus, populating the partially folded conformations that are likely responsible for the death of neurons (27, 28) . This may occur before aggregation toward Lewy bodies that might have a protective role (29) . Whereas the etiology of idiopathic parkinsonism remains a complex puzzle of genes, environment, and aging (30) , Lewy body formation may also occur in a relatively young brain, as shown by our vCJD case.
Although the present study focused on the nigrostriatal pathway and on possible overlaps between prion and >-synuclein pathologies, there may also be overlaps that involve A-amyloid and tau protein (7) . These issues require further investigation. Large autopsy series are necessary for elucidating correlations between clinical features, neurodegeneration, Lewy bodies, and coexisting pathologies in the aged brain (31) .
